LASMIDITAN SUCCINATE
| Brand name | REYVOW |
|---|---|
| Active ingredient | LASMIDITAN SUCCINATE |
| Strength | EQ 200MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | December 2020 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 11053214 | December 2037 | substance, product |
| 12257246 | July 2030 | use U-2718 |
| 7423050 | February 2028 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.